‘November collective immunity’, the government… A lot of variables, anxiety

The government is also thinking about repaying the vaccine after borrowing it from the United States, but stressed that that didn’t hurt the vaccination plan.

So, as planned, group immunization is possible in November of this year, but reporter Kim Yong-tae pointed out the current vaccine supply and demand situation and the remaining variables.

<기자>

The amount of vaccines introduced by the government this year is about 150 million doses.

It’s a generous amount for 79 million people to inoculate, but the problem is speed.

The vaccines that were confirmed to be introduced in the first half of this year are about 18 million doses, both of which are AstraZeneca and Pfizer vaccines, accounting for about 12% of the total volume this year.

Modena, Novavex, and Janssen vaccines, which have the largest contract volume, are uncertain about introduction in the first half of the year.

The number of people who received the vaccine at least once was 1639,000, accounting for only 3.15% of the total population, but the government was still confident in achieving mass immunity in November.

It is explained that it is possible to increase the vaccination rate by increasing the vaccination center and to secure additional vaccines at the same time.

Specific timetables such as the 1st vaccination of 3 million people this month and the 1st vaccination of 12 million people in the first half of this month are also unchanged.

[홍정익/질병관리청 예방접종기획팀장 : 2차 접종까지 하면, 11월까지 3,600만 명에 대한 2차 접종까지 완료할 수 있을 것으로 보이고….]

However, it is difficult to guarantee the achievement of the goal with external variables that come out one after another.

The U.S. Food and Drug Administration (FDA) and the FDA put an end to production at the Janssen vaccine factory in Baltimore, where an accident occurred due to incorrect mixing of vaccine ingredients. Is known.

News such as Modena’s US priority supply policy and review of the need for a tertiary vaccination may act as an unsettling factor in Korea’s vaccine supply and demand.

(Video coverage: Kim Min-cheol, Video editing: Jeong Seong-hoon)

▶ “Not possible in mode or in the first half”… “Korea-US Vaccine Swap Consultation”

.Source